ClinicalTrials.gg
CompletedNCT03054350Updated Apr 8, 2021Results posted

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

A Phase 2 interventional study of Vadadustat and Placebo in Anemia and Dialysis Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
14th of 27
60 · median 60
Started
2016
with 4 others
Phase 2
8 of 27
none open now
Registered
12th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 14th largest by enrollment, is one of 5 that started in 2016, is one of 8 in phase 2, and was the 12th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of orally administered vadadustat in Japanese participants with anemia secondary to Dialysis-dependent Chronic Kidney Disease (DD-CKD).

03

Conditions studied

  • Anemia
  • Dialysis Dependent Chronic Kidney Disease

Browse trials for

Keywords

  • Anemia
  • kidney
  • dialysis dependent chronic kidney disease
  • CKD
  • DD
  • renal
  • vadadustat
  • AKB-6548
  • hypoxia-inducible factor
  • Akebia (AKB)
  • hypoxia-inducible factor (HIF)
  • HIF
  • prolyl-hydroxylase inhibitor (PHI)
  • PHI
  • Japan
  • Japanese
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female Japanese participants ≥20 years of age
  • Receiving chronic maintenance hemodialysis for end-stage kidney disease
  • (Hb) \<10.0 grams per deciliter (g/dL)

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than chronic kidney disease (CKD) or presence of active bleeding or recent blood loss
  • Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic , myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
  • Red blood cell transfusion within 4 weeks prior to or during screening
  • Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Vadadustat, Dose 1

    Daily oral dose

    Drug: Vadadustat

  • Experimental
    Vadadustat, Dose 2

    Daily oral dose

    Drug: Vadadustat

  • Experimental
    Vadadustat, Dose 3

    Daily oral dose

    Drug: Vadadustat

  • Placebo comparator
    Placebo

    Daily oral dose

    Drug: Placebo

Interventions

  • Daily oral dose

    Also known as: AKB-6548

  • DrugPlacebo

    Daily oral dose

06

What researchers measure

Primary outcomes

  1. Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period

    The pre-treatment average value for Hb was defined as the average of 3 values obtained prior to treatment, i.e., the qualifying screening value and the Baseline value. Change from Pre-treatment was calculated as the Week 6 value minus the Pre-treatment value.

    Time frame: Pre-treatment; Week 6

Secondary outcomes

  1. Time to Reach the Target Hb Level of 10.0 to 12.0 g/dL From Baseline up to Week 16

    Time for this analysis was measured from Day 1 (Baseline) through the point in time during either the Primary Efficacy Period or the Dose Adjustment and Maintenance Period when a participant's Hb level achieved the target range of 10.0 to 12.0 g/dL.

    Time frame: from Baseline up to Week 16

  2. Mean Hb Levels at the End of the Primary Efficacy Period

    Data are reported as mean of the actual Week 6 values.

    Time frame: up to Week 6

  3. Mean Hb Levels at the End of the Dose Adjustment and Maintenance Period

    Data are reported as mean of the actual Week 16 values.

    Time frame: up to Week 16

  4. Number of Participants Who Achieved the Target Hb Level of 10.0 to 12.0 g/dL at the End of the Dose Adjustment and Maintenance Period

    Time frame: up to Week 16

  5. Mean Change in Hb Between Pre-treatment and the End of the Dose Adjustment and Maintenance Period

    A pre-treatment average value for Hb was defined as the average of 3 values obtained prior to dosing, i.e., the 2 qualifying screening values and the Baseline value. Change from Pre-treatment was calculated as the Week 16 value minus the Pre-treatment value.

    Time frame: Pre-treatment; Week 16

  6. Mean Change in Red Blood Cell (RBC) Count and Absolute Reticulocyte Count From Baseline to the End of the Primary Efficacy Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 6

  7. Mean Change in RBC Count and Absolute Reticulocyte Count From Baseline to the End of the Dose Adjustment and Maintenance Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 16

  8. Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Primary Efficacy Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 6

  9. Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Dose Adjustment and Maintenance Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 16

  10. Mean Change in Iron and Total Iron Binding Capacity (TIBC) From Baseline to the End of the Primary Efficacy Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 6

  11. Mean Change in Iron and TIBC From Baseline to the End of the Dose Adjustment and Maintenance Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 16

  12. Mean Change in Transferrin Saturation (TSAT) From Baseline to the End of the Primary Efficacy Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 6

  13. Mean Change in TSAT From Baseline to the End of the Dose Adjustment and Maintenance Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 16

  14. Mean Change in Ferritin and Hepcidin From Baseline to the End of the Primary Efficacy Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 6

  15. Mean Change in Ferritin and Hepcidin From Baseline to the End of the Dose Adjustment and Maintenance Period

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 16

  16. Number of Participants Who Required Rescue With a RBC Transfusion From Baseline to the End of the Primary Efficacy Period

    Participants who initiated rescue therapy (including RBC transfusion) were required to stop study drug treatment and were discontinued from the study.

    Time frame: Baseline; Week 6

  17. Number of Participants Who Required Rescue With RBC Transfusion From Baseline to the End of the Dose Adjustment and Maintenance Period

    Participants who initiated rescue therapy (including RBC transfusion) were required to stop study drug treatment and were discontinued from the study.

    Time frame: Baseline; Week 16

  18. Number of Participants Who Required Rescue With Erythropoiesis-Stimulating Agents (ESAs) From Baseline to the End of the Primary Efficacy Period

    ESA rescue is defined as participants with ESA administration and 1) the participant experienced a clinically significant worsening of their anemia or symptoms of anemia, 2) the participant's Hb level is \<9.0 g/dL, and 3) reason for early study withdrawal of worsening of anemia requiring ESA rescue or blood transfusion. Participants who initiated rescue therapy (including ESAs) were required to stop study drug treatment and were discontinued from the study.

    Time frame: Baseline; Week 6

  19. Number of Participants Who Required Rescue With ESAs From Baseline to the End of the Dose Adjustment and Maintenance Period

    ESA rescue is defined as participants with ESA administration and 1) the participant experienced a clinically significant worsening of their anemia or symptoms of anemia, 2) the participant's Hb level is \<9.0 g/dL, and 3) reason for early study withdrawal of worsening of anemia requiring ESA rescue or blood transfusion. Participants who initiated rescue therapy (including ESAs) were required to stop study drug treatment and were discontinued from the study.

    Time frame: Baseline; Week 16

  20. Number of the Participants With the Indicated Number of Dose Adjustments From Baseline to the End of the Dose Adjustment and Maintenance Period

    Increases in dose were not allowed during the 6-week Primary Efficacy Period.

    Time frame: up to Week 16

  21. Plasma Concentration Profile of Vadadustat and Its Metabolites Using a Pre-dose Sample From Week 4

    Blood samples were collected for analysis.

    Time frame: Week 4, pre-dose

  22. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) in the Primary Efficacy Period

    An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. An AE that met one or more of the following criteria or outcomes was classified as serious: death; life-threatening; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; was considered a medically important event not meeting the above criteria, but which could jeopardize a participant, or could require medical or surgical intervention to prevent one of the criteria listed in this definition.

    Time frame: up to Week 6

  23. Number of Participants With TEAEs and Treatment-emergent SAEs in the Dose Adjustment and Maintenance Period

    An AE was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. An AE that met one or more of the following criteria or outcomes was classified as serious: death; life-threatening; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; was considered a medically important event not meeting the above criteria, but which could jeopardize a participant, or could require medical or surgical intervention to prevent one of the criteria listed in this definition.

    Time frame: up to Week 16

07

Results

Posted Apr 8, 2021

Participant flow

Primary Efficacy Period (6 Weeks)
Participant flow — Primary Efficacy Period (6 Weeks)
MilestoneVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Started151515555
Completed111313312
Not completed422243
Withdrew: Esa rescue/blood transfusion for anemia421243
Withdrew: Withdrawal by subject001000
Dose Adjustment and Maintenance Period
Participant flow — Dose Adjustment and Maintenance Period
MilestoneVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Started111313312
Completed101312212
Not completed101100
Withdrew: Esa rescue/blood transfusion for anemia100100
Withdrew: Captured as other001000

Outcome measures

PrimaryMean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period

The pre-treatment average value for Hb was defined as the average of 3 values obtained prior to treatment, i.e., the qualifying screening value and the Baseline value. Change from Pre-treatment was calculated as the Week 6 value minus the Pre-treatment value.

Time frame:
Pre-treatment; Week 6
Reported as:
Least squares mean · grams per deciliter (g/dL)
Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period
grams per deciliter (g/dL)Vadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period-0.28 ± 0.2180.08 ± 0.2220.41 ± 0.233-1.48 ± 0.226
Statistical analysis
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.0004 · Least squares mean difference: 1.19 · 95% CI 0.56 to 1.82The analysis of covariance (ANCOVA) model includes treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: 1.56 · 95% CI 0.93 to 2.19The ANCOVA model includes treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: 1.89 · 95% CI 1.23 to 2.54The ANCOVA model includes treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
SecondaryTime to Reach the Target Hb Level of 10.0 to 12.0 g/dL From Baseline up to Week 16

Time for this analysis was measured from Day 1 (Baseline) through the point in time during either the Primary Efficacy Period or the Dose Adjustment and Maintenance Period when a participant's Hb level achieved the target range of 10.0 to 12.0 g/dL.

Time frame:
from Baseline up to Week 16
Reported as:
Mean · days
Time to Reach the Target Hb Level of 10.0 to 12.0 g/dL From Baseline up to Week 16
daysVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Time to Reach the Target Hb Level of 10.0 to 12.0 g/dL From Baseline up to Week 1669.3 ± 25.3179.2 ± 24.9454.6 ± 27.90—57.0 ± 19.8085.0 ± NA
SecondaryMean Hb Levels at the End of the Primary Efficacy Period

Data are reported as mean of the actual Week 6 values.

Time frame:
up to Week 6
Reported as:
Mean · g/dL
Mean Hb Levels at the End of the Primary Efficacy Period
g/dLVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Mean Hb Levels at the End of the Primary Efficacy Period9.064 ± 1.06529.062 ± 0.84129.969 ± 0.72967.817 ± 1.4662
SecondaryMean Hb Levels at the End of the Dose Adjustment and Maintenance Period

Data are reported as mean of the actual Week 16 values.

Time frame:
up to Week 16
Reported as:
Mean · g/dL
Mean Hb Levels at the End of the Dose Adjustment and Maintenance Period
g/dLVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Mean Hb Levels at the End of the Dose Adjustment and Maintenance Period10.460 ± 0.750111.285 ± 1.784111.100 ± 1.14028.600 ± 0.989913.200 ± NA12.100 ± 1.5556
SecondaryNumber of Participants Who Achieved the Target Hb Level of 10.0 to 12.0 g/dL at the End of the Dose Adjustment and Maintenance Period
Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved the Target Hb Level of 10.0 to 12.0 g/dL at the End of the Dose Adjustment and Maintenance Period
ParticipantsVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Number of Participants Who Achieved the Target Hb Level of 10.0 to 12.0 g/dL at the End of the Dose Adjustment and Maintenance Period7117001
SecondaryMean Change in Hb Between Pre-treatment and the End of the Dose Adjustment and Maintenance Period

A pre-treatment average value for Hb was defined as the average of 3 values obtained prior to dosing, i.e., the 2 qualifying screening values and the Baseline value. Change from Pre-treatment was calculated as the Week 16 value minus the Pre-treatment value.

Time frame:
Pre-treatment; Week 16
Reported as:
Mean · g/dL
Mean Change in Hb Between Pre-treatment and the End of the Dose Adjustment and Maintenance Period
g/dLVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Mean Change in Hb Between Pre-treatment and the End of the Dose Adjustment and Maintenance Period1.397 ± 0.57552.444 ± 1.78071.644 ± 1.4973-0.233 ± 0.14143.800 ± NA3.000 ± 0.2828
SecondaryMean Change in Red Blood Cell (RBC) Count and Absolute Reticulocyte Count From Baseline to the End of the Primary Efficacy Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 6
Reported as:
Least squares mean · 10^6 cells/microliter (µL)
Mean Change in Red Blood Cell (RBC) Count and Absolute Reticulocyte Count From Baseline to the End of the Primary Efficacy Period
10^6 cells/microliter (µL)Vadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
RBC Count-0.01 ± 0.0730.08 ± 0.0690.20 ± 0.069-0.30 ± 0.099
Absolute Reticulocyte Count0.02 ± 0.0050.02 ± 0.0040.03 ± 0.0040.01 ± 0.006
Statistical analysis
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.0232 · Least squares mean difference: 0.29 · 95% CI 0.04 to 0.54The ANCOVA model will include treatment assignment (3 dosed groups;1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.0033 · Least squares mean difference: 0.38 · 95% CI 0.13 to 0.62The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = 0.0002 · Least squares mean difference: 0.50 · 95% CI 0.26 to 0.74The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.3289 · Least squares mean difference: 0.01 · 94% CI -0.01 to 0.02The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.2607 · Least squares mean difference: 0.01 · 95% CI -0.01 to 0.02The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = 0.0252 · Least squares mean difference: 0.02 · 95% CI 0.00 to 0.03The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
SecondaryMean Change in RBC Count and Absolute Reticulocyte Count From Baseline to the End of the Dose Adjustment and Maintenance Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Mean · 10^6 cells/µL
Mean Change in RBC Count and Absolute Reticulocyte Count From Baseline to the End of the Dose Adjustment and Maintenance Period
10^6 cells/µLVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
RBC Count0.454 ± 0.22250.819 ± 0.51270.503 ± 0.50560.065 ± 0.02121.160 ± NA1.035 ± 0.0778
Absolute Reticulocyte Count0.017 ± 0.01690.021 ± 0.01800.016 ± 0.01620.016 ± 0.00830.024 ± NA0.014 ± 0.0217
SecondaryMean Change in Hematocrit and Reticulocytes From Baseline to the End of the Primary Efficacy Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 6
Reported as:
Least squares mean · percentage
Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Primary Efficacy Period
percentageVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Hematocrit0.67 ± 0.7701.98 ± 0.7373.30 ± 0.737-2.63 ± 1.045
Reticulocytes0.64 ± 0.1580.57 ± 0.1410.71 ± 0.1400.39 ± 0.212
Statistical analysis
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.0154 · Least squares mean difference: 3.31 · 95% CI 0.67 to 5.94The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.0008 · Least squares mean difference: 4.61 · 95% CI 2.06 to 7.16The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: 5.93 · 95% CI 3.31 to 8.56The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.3572 · Least squares mean difference: 0.25 · 95% CI -0.30 to 0.81The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.4758 · Least squares mean difference: 0.18 · 95% CI -0.33 to 0.69The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = 0.2048 · Least squares mean difference: 0.33 · 95% CI -0.19 to 0.84The ANCOVA model will include treatment assignment (3 dosed groups; 1 placebo group) and pre-treatment Hb value as a covariate.
SecondaryMean Change in Hematocrit and Reticulocytes From Baseline to the End of the Dose Adjustment and Maintenance Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Mean · percentage
Mean Change in Hematocrit and Reticulocytes From Baseline to the End of the Dose Adjustment and Maintenance Period
percentageVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Hematocrit5.12 ± 2.1058.92 ± 5.1005.63 ± 4.9211.20 ± 0.00012.90 ± NA10.70 ± 1.697
Reticulocytes0.32 ± 0.6360.33 ± 0.6860.24 ± 0.5470.55 ± 0.2120.40 ± NA0.15 ± 0.636
SecondaryMean Change in Iron and Total Iron Binding Capacity (TIBC) From Baseline to the End of the Primary Efficacy Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 6
Reported as:
Mean · micrograms per deciliter (μg/dL)
Mean Change in Iron and Total Iron Binding Capacity (TIBC) From Baseline to the End of the Primary Efficacy Period
micrograms per deciliter (μg/dL)Vadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Iron-3.3 ± 26.60-1.5 ± 19.50-8.1 ± 21.95-1.5 ± 26.64
TIBC35.4 ± 28.7267.5 ± 25.7280.7 ± 39.0415.8 ± 8.08
Statistical analysis
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.9373test of treatment group difference based on ANCOVA model
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.6623test of treatment group difference based on ANCOVA model
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = 0.9374test of treatment group difference based on ANCOVA model
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.2085test of treatment group difference based on ANCOVA model
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.0016test of treatment group difference based on ANCOVA model
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = 0.0001test of treatment group difference based on ANCOVA model
SecondaryMean Change in Iron and TIBC From Baseline to the End of the Dose Adjustment and Maintenance Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Mean · μg/dL
Mean Change in Iron and TIBC From Baseline to the End of the Dose Adjustment and Maintenance Period
μg/dLVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Iron-18.5 ± 24.01-8.7 ± 24.290.9 ± 48.22-9.5 ± 30.41-7.0 ± NA15.0 ± 43.84
TIBC58.5 ± 44.1280.9 ± 29.4285.4 ± 39.9133.0 ± 2.83108.0 ± NA78.0 ± 62.23
SecondaryMean Change in Transferrin Saturation (TSAT) From Baseline to the End of the Primary Efficacy Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 6
Reported as:
Mean · percentage
Mean Change in Transferrin Saturation (TSAT) From Baseline to the End of the Primary Efficacy Period
percentageVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Mean Change in Transferrin Saturation (TSAT) From Baseline to the End of the Primary Efficacy Period-6.51 ± 11.621-10.14 ± 11.294-12.46 ± 9.544-2.78 ± 12.822
Statistical analysis
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.2708test of treatment group difference based on ANCOVA model
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.0966test of treatment group difference based on ANCOVA model
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = 0.0424test of treatment group difference based on ANCOVA model
SecondaryMean Change in TSAT From Baseline to the End of the Dose Adjustment and Maintenance Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Mean · percentage
Mean Change in TSAT From Baseline to the End of the Dose Adjustment and Maintenance Period
percentageVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Mean Change in TSAT From Baseline to the End of the Dose Adjustment and Maintenance Period-14.25 ± 12.069-13.79 ± 13.549-10.93 ± 12.627-12.50 ± 18.526-17.10 ± NA-4.70 ± 12.021
SecondaryMean Change in Ferritin and Hepcidin From Baseline to the End of the Primary Efficacy Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 6
Reported as:
Mean · nanograms per milliliter (ng/mL)
Mean Change in Ferritin and Hepcidin From Baseline to the End of the Primary Efficacy Period
nanograms per milliliter (ng/mL)Vadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Ferritin-51.20 ± 58.855-68.67 ± 54.707-104.49 ± 49.55812.63 ± 32.424
Hepcidin-53.465 ± 43.5531-73.587 ± 32.3547-104.301 ± 36.7636-11.802 ± 13.6518
Statistical analysis
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.0207test of treatment group difference based on ANCOVA model
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.0022test of treatment group difference based on ANCOVA model
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = <0.0001test of treatment group difference based on ANCOVA model
  • Vadadustat 150 mg vs Placebo · ANCOVA · p = 0.0062test of treatment group difference based on ANCOVA model
  • Vadadustat 300 mg vs Placebo · ANCOVA · p = 0.0002test of treatment group difference based on ANCOVA model
  • Vadadustat 600 mg vs Placebo · ANCOVA · p = <0.0001 (test of treatment group difference based on ANCOVA model)
SecondaryMean Change in Ferritin and Hepcidin From Baseline to the End of the Dose Adjustment and Maintenance Period

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 16
Reported as:
Mean · ng/mL
Mean Change in Ferritin and Hepcidin From Baseline to the End of the Dose Adjustment and Maintenance Period
ng/mLVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Ferritin-105.09 ± 55.837-119.28 ± 84.000-113.52 ± 54.559-43.05 ± 81.954-150.70 ± NA-76.95 ± 42.356
Hepcidin-73.826 ± 50.9042-99.367 ± 51.3174-106.838 ± 40.1472-95.940 ± 98.7262-122.300 ± NA-35.140 ± 62.9184
SecondaryNumber of Participants Who Required Rescue With a RBC Transfusion From Baseline to the End of the Primary Efficacy Period

Participants who initiated rescue therapy (including RBC transfusion) were required to stop study drug treatment and were discontinued from the study.

Time frame:
Baseline; Week 6
Reported as:
Count of participants · Participants
Number of Participants Who Required Rescue With a RBC Transfusion From Baseline to the End of the Primary Efficacy Period
ParticipantsVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Number of Participants Who Required Rescue With a RBC Transfusion From Baseline to the End of the Primary Efficacy Period0013
SecondaryNumber of Participants Who Required Rescue With RBC Transfusion From Baseline to the End of the Dose Adjustment and Maintenance Period

Participants who initiated rescue therapy (including RBC transfusion) were required to stop study drug treatment and were discontinued from the study.

Time frame:
Baseline; Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Required Rescue With RBC Transfusion From Baseline to the End of the Dose Adjustment and Maintenance Period
ParticipantsVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Number of Participants Who Required Rescue With RBC Transfusion From Baseline to the End of the Dose Adjustment and Maintenance Period100000
SecondaryNumber of Participants Who Required Rescue With Erythropoiesis-Stimulating Agents (ESAs) From Baseline to the End of the Primary Efficacy Period

ESA rescue is defined as participants with ESA administration and 1) the participant experienced a clinically significant worsening of their anemia or symptoms of anemia, 2) the participant's Hb level is \<9.0 g/dL, and 3) reason for early study withdrawal of worsening of anemia requiring ESA rescue or blood transfusion. Participants who initiated rescue therapy (including ESAs) were required to stop study drug treatment and were discontinued from the study.

Time frame:
Baseline; Week 6
Reported as:
Count of participants · Participants
Number of Participants Who Required Rescue With Erythropoiesis-Stimulating Agents (ESAs) From Baseline to the End of the Primary Efficacy Period
ParticipantsVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Number of Participants Who Required Rescue With Erythropoiesis-Stimulating Agents (ESAs) From Baseline to the End of the Primary Efficacy Period4218
SecondaryNumber of Participants Who Required Rescue With ESAs From Baseline to the End of the Dose Adjustment and Maintenance Period

ESA rescue is defined as participants with ESA administration and 1) the participant experienced a clinically significant worsening of their anemia or symptoms of anemia, 2) the participant's Hb level is \<9.0 g/dL, and 3) reason for early study withdrawal of worsening of anemia requiring ESA rescue or blood transfusion. Participants who initiated rescue therapy (including ESAs) were required to stop study drug treatment and were discontinued from the study.

Time frame:
Baseline; Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Required Rescue With ESAs From Baseline to the End of the Dose Adjustment and Maintenance Period
ParticipantsVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
Number of Participants Who Required Rescue With ESAs From Baseline to the End of the Dose Adjustment and Maintenance Period000100
SecondaryNumber of the Participants With the Indicated Number of Dose Adjustments From Baseline to the End of the Dose Adjustment and Maintenance Period

Increases in dose were not allowed during the 6-week Primary Efficacy Period.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of the Participants With the Indicated Number of Dose Adjustments From Baseline to the End of the Dose Adjustment and Maintenance Period
ParticipantsVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
0 dose adjustments539233
1 dose adjustment222100
2 dose adjustments583112
3 or more dose adjustments320100
SecondaryPlasma Concentration Profile of Vadadustat and Its Metabolites Using a Pre-dose Sample From Week 4

Blood samples were collected for analysis.

Time frame:
Week 4, pre-dose
Reported as:
Geometric mean · μg/mL
Plasma Concentration Profile of Vadadustat and Its Metabolites Using a Pre-dose Sample From Week 4
μg/mLVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
Vadadustat4343.54 ± 175.177561.36 ± 134.7715083.03 ± 46.77—
O-glucuronide8667.97 ± 73.7914623.89 ± 67.4436476.33 ± 57.18—
Acyl-glucuronide12.019 ± 16.5512.174 ± 8.1022.765 ± 70.53—
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) in the Primary Efficacy Period

An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. An AE that met one or more of the following criteria or outcomes was classified as serious: death; life-threatening; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; was considered a medically important event not meeting the above criteria, but which could jeopardize a participant, or could require medical or surgical intervention to prevent one of the criteria listed in this definition.

Time frame:
up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) in the Primary Efficacy Period
ParticipantsVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo
TEAEs81166
Treatment-emergent SAEs0031
SecondaryNumber of Participants With TEAEs and Treatment-emergent SAEs in the Dose Adjustment and Maintenance Period

An AE was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. An AE that met one or more of the following criteria or outcomes was classified as serious: death; life-threatening; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; was considered a medically important event not meeting the above criteria, but which could jeopardize a participant, or could require medical or surgical intervention to prevent one of the criteria listed in this definition.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and Treatment-emergent SAEs in the Dose Adjustment and Maintenance Period
ParticipantsVadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mg
TEAEs999112
Treatment-emergent SAEs111000

Adverse events

Collected over up to Week 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primary Efficacy Period: 150 mg Vadadustat8/15 (53.3%)0/15 (0%)8/15 (53.3%)
Primary Efficacy Period: 300 mg Vadadustat11/15 (73.3%)0/15 (0%)11/15 (73.3%)
Primary Efficacy Period: 600 mg Vadadustat6/15 (40%)3/15 (20%)5/15 (33.3%)
Primary Efficacy Period: Placebo Matched to 150 mg Vadadustat2/5 (40%)0/5 (0%)2/5 (40%)
Primary Efficacy Period: Placebo Matched to 300 mg Vadadustat2/5 (40%)1/5 (20%)2/5 (40%)
Primary Efficacy Period: Placebo Matched to 600 mg Vadadustat2/5 (40%)0/5 (0%)2/5 (40%)
Dose Adjustment and Maintenance: 150 mg Vadadustat9/15 (60%)1/15 (6.7%)9/15 (60%)
Dose Adjustment and Maintenance: 300 mg Vadadustat9/15 (60%)1/15 (6.7%)9/15 (60%)
Dose Adjustment and Maintenance: 600 mg Vadadustat9/15 (60%)1/15 (6.7%)9/15 (60%)
Dose Adjustment and Maintenance: Placebo to 150 mg Vadadustat1/5 (20%)0/5 (0%)1/5 (20%)
Dose Adjustment and Maintenance: Placebo to 300 mg Vadadustat1/5 (20%)0/5 (0%)1/5 (20%)
Dose Adjustment and Maintenance: Placebo to 600 mg Vadadustat2/5 (40%)0/5 (0%)2/5 (40%)
Most frequent serious events
Most frequent serious events
EventPrimary Efficacy Period: 150 mg VadadustatPrimary Efficacy Period: 300 mg VadadustatPrimary Efficacy Period: 600 mg VadadustatPrimary Efficacy Period: Placebo Matched to 150 mg VadadustatPrimary Efficacy Period: Placebo Matched to 300 mg VadadustatPrimary Efficacy Period: Placebo Matched to 600 mg VadadustatDose Adjustment and Maintenance: 150 mg VadadustatDose Adjustment and Maintenance: 300 mg VadadustatDose Adjustment and Maintenance: 600 mg VadadustatDose Adjustment and Maintenance: Placebo to 150 mg VadadustatDose Adjustment and Maintenance: Placebo to 300 mg VadadustatDose Adjustment and Maintenance: Placebo to 600 mg Vadadustat
Arteriovenous fistula site complicationInjury, poisoning and procedural complications0/150/150/150/51/50/50/150/150/150/50/50/5
PericarditisCardiac disorders0/150/151/150/50/50/50/150/150/150/50/50/5
Gastric ulcer haemorrhageGastrointestinal disorders0/150/150/150/50/50/51/150/150/150/50/50/5
Cholecystitis acuteHepatobiliary disorders0/150/151/150/50/50/50/150/150/150/50/50/5
Enteritis infectiousInfections and infestations0/150/151/150/50/50/50/150/150/150/50/50/5
Shunt stenosisInjury, poisoning and procedural complications0/150/151/150/50/50/50/151/150/150/50/50/5
Cerebral haemorrhageNervous system disorders0/150/150/150/50/50/51/150/150/150/50/50/5
Toxic encephalopathyNervous system disorders0/150/151/150/50/50/50/150/150/150/50/50/5
AnxietyPsychiatric disorders0/150/150/150/50/50/50/150/151/150/50/50/5
Most frequent other events
Showing 10 of 62
Most frequent other events
EventPrimary Efficacy Period: 150 mg VadadustatPrimary Efficacy Period: 300 mg VadadustatPrimary Efficacy Period: 600 mg VadadustatPrimary Efficacy Period: Placebo Matched to 150 mg VadadustatPrimary Efficacy Period: Placebo Matched to 300 mg VadadustatPrimary Efficacy Period: Placebo Matched to 600 mg VadadustatDose Adjustment and Maintenance: 150 mg VadadustatDose Adjustment and Maintenance: 300 mg VadadustatDose Adjustment and Maintenance: 600 mg VadadustatDose Adjustment and Maintenance: Placebo to 150 mg VadadustatDose Adjustment and Maintenance: Placebo to 300 mg VadadustatDose Adjustment and Maintenance: Placebo to 600 mg Vadadustat
NasopharyngitisInfections and infestations1/155/151/150/50/50/54/152/150/150/51/50/5
DiarrhoeaGastrointestinal disorders0/152/152/151/50/50/50/151/150/151/50/51/5
Pancreatic cystGastrointestinal disorders0/150/150/150/50/51/50/150/150/150/50/50/5
Chest discomfortGeneral disorders0/150/150/150/51/50/50/150/150/150/50/50/5
Herpes zosterInfections and infestations0/150/151/150/50/50/50/150/150/150/50/51/5
PneumoniaInfections and infestations1/150/150/150/50/50/50/150/150/151/50/50/5
ContusionInjury, poisoning and procedural complications0/150/151/150/51/50/52/150/150/150/50/50/5
ExcoriationInjury, poisoning and procedural complications0/150/150/150/50/51/50/150/150/150/50/50/5
ArthralgiaMusculoskeletal and connective tissue disorders1/150/150/151/50/50/51/150/150/150/50/50/5
Musculoskeletal painMusculoskeletal and connective tissue disorders0/150/150/150/51/50/50/150/150/150/50/50/5

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all enrolled participants who received at least 1 dose of study medication. The Safety Population was based on the actual treatment that participants received.

Age, Continuous
Age, Continuous(years)Vadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mgTotal
Mean61.5 ± 11.0164.3 ± 8.0265.1 ± 9.0560.8 ± 12.8561.0 ± 15.6070.8 ± 8.2363.8 ± 10.16
Sex: Female, Male
Sex: Female, Male(Participants)Vadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mgTotal
Female52523219
Male10131032341
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Vadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mgTotal
Count of participants——————0
Hemoglobin Levels
Hemoglobin Levels(grams per deciliter (g/dL))Vadadustat 150 mgVadadustat 300 mgVadadustat 600 mgPlacebo to Vadadustat 150 mgPlacebo to Vadadustat 300 mgPlacebo to Vadadustat 600 mgTotal
Mean8.996 ± 0.52298.793 ± 0.52549.317 ± 0.62228.827 ± 0.64058.950 ± 0.73319.133 ± 0.67379.015 ± 0.5935
08

Study locations

18 sites
  • Aichi, Japan
  • Ehime, Japan
  • Fukui, Japan
  • Hiroshima, Japan
  • Hokkaido, Japan
  • Hyogo, Japan
  • Ibaraki, Japan
  • Kagoshima, Japan
  • Kochi, Japan
  • Miyagi, Japan
  • Nagano, Japan
  • Nagasaki, Japan
  • Niigata, Japan
  • Oita, Japan
  • Okinawa, Japan
  • Osaka, Japan
  • Saitama, Japan
  • Shizuoka, Japan
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Oct 2017, 10 months.

Results were first posted in Apr 2021, 3 years 5 months after primary completion. A results delay was requested in Nov 2018.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 10 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2017
First posted
Feb 15, 2017
StartActual
Dec 2016
Primary completionActual
Oct 24, 2017
CompletionActual
Jan 24, 2018
Results delay requested
Nov 7, 2018
Results first posted
Apr 8, 2021
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03054350
Responsible party
Sponsor
First posted
Feb 15, 2017
Start date
Dec 2016
Primary completion
Oct 24, 2017
Completion
Jan 24, 2018
Results posted
Apr 8, 2021
Last update
Apr 8, 2021

Study contacts

Akebia Therapeutics
study director · Sponsor GmbH

Oversight

FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion